Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDK4/6 Pharmacokinetics in Healthy Volunteers With CYP3A4*22 Genotype
NCT05691400Phase 4Withdrawn
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Mar 2024
- Primary completion
- Mar 2027
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of palbociclib, ribociclib, abemaciclib in breast cancer, sponsored by University of Michigan Rogel Cancer Center. Planned start Mar 2024; status: withdrawn.
02
Drugs
palbociclibribociclibabemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05691400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05691400.